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Background: For coronary interventions the arterial access via the radial artery is associated with fewer vascular
access site complications, and has been shown to reduce major bleeding when compared to the femoral
approach. But the endomyocardial biopsy (EMB) approach is usually done by a transfemoral or cervical access
known to be associated with an increased risk of artery puncture and its potential complications (i.e., false
aneurysm, artery-venous fistula), and moreover needs post-procedural immobilization. A transradial approach for
EMBs is not standardized. The aim of our study is to validate safety and efficacy of the transradial access approach
for left ventricular EMB, and to define patients eligible for a safe and successful procedure.
Methods and Results: We evaluated the transradial access using a 7.5 F sheathless multipurpose guiding catheter
to obtain EMB from the left ventricle (LV). 18 patients were included. The transradial success rate was 100% (18/18).
There were no periprocedural cardiac complications. Immediate post-procedural ambulation could be achieved in
all patients. Although radial artery pulse was confirmed by ultrasonic vascular Doppler after removal of the guide
in 100% (18/18) of the patients, 50% (9/18) of the patients showed occlusion of the radial artery (RAO) by duplex
sonography proximal to the access site (RAO group). 33% (3/9) of the patients in the RAO group, and 11,1% (1/9)
of the patients in the patent radial artery (RAP) group, respectively, experienced mild pain in the right lower arm
after the procedure. Color Doppler ultrasonography of the right radial artery performed 24 h after the procedure
revealed radial occlusion in 50% (9/18) of the patients. The diameter of the radial artery was significantly smaller in
the RAO group (p = 0,034), and peak systolic velocity (PSV) of the right ulnar artery was significantly higher in the
RAO group (p = 0.012). In comparison, peak systolic velocity of the opposite radial artery was significantly lower
(p = 0,045). Gender, diabetes, radial artery inner diameter ≤2.5 mm and lower peak systolic velocity of < 50 cm/s
are predictors of RAO.
Conclusion: The present study demonstrates the safety and efficacy of a transradial access for EMB using a
hydrophilic sheathless guiding catheter.
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Endomyocardial biopsy (EMB) is the technique of choice
in the diagnosis of adults presenting with cardiomyopathy
of unknown origin. The toxic, infectious-inflammatory, in-
filtrative or autoimmune processes that cause cardiac dys-
function occur at a cellular level and no other diagnostic
techniques can establish the nature of the etiological
agent. As well as detection of inflammation or viral ge-
nomes in the acute phase of myocarditis, EMB adds im-
portant prognostic information, which may translate to
decisive therapeutic decisions [1, 2].
The 2007 American Heart Association/American College
of Cardiology Foundation/European Society of Cardiology
scientific statement on EMB limited its class I recommen-
dations to unexplained new-onset heart failure of less than
2 weeks duration associated with hemodynamic comprom-
ise or unexplained new onset heart failure of 2 weeks to
3 months duration associated with a dilated left ventricle
and new ventricular arrhythmias or conduction distur-
bances [3]. However, in a recent position statement from
the ESC [1], the recommendation for EMB was extended,
including patients with a pseudo-infarct presentation after
excluding coronary artery disease, myocarditis and inflam-
matory cardiomyopathies, as well as for patients with rap-
idly advancing cardiomyopathy refractory to conventional
therapy. This change responds to the more widespread
availability of immunohistochemical and viral genome de-
tection techniques, which improve the ability to detect the
underlying cause of myocarditis. Hence, an increasing num-
ber of patients can benefit from specific treatment.
Moreover, EMB are routinely performed in daily prac-
tice for post heart transplant patients most commonly in
centres with post heart transplant patients.
Furthermore, the choice of the ventricular site for
EMB is still under debate. Whereas some observe that
diagnostic yield of left ventricle (LV) EMB is superior to
right ventricular (RV) EMB when routine immunohisto-
chemistry and viral genome amplification are used in
suspected LV myocarditis, more recent data state that
both procedures are similar when assessing inflamma-
tion or viral genome in the myocardium. However, we
recently showed morphological changes such as intersti-
tial fibrosis and cardiac collagen type I expression were
more reliably found in LV EMB [4].
RV-EMB approached by right internal jugular or fem-
oral vein, and LV-EMB approached by the left or right
femoral artery are commonly used, and when performed
by experienced operators, both right and left ventricular
EMB have low complication rates. In a single center
study that analyzed 3,048 EMB in a non-transplant set-
ting, the risk of major complications including cardiac
tamponade and AV block requiring permanent pace-
maker implantation was 0,12% [5, 6]. Chimenti et al.
documented that over a 28-year period and over 4,000EMB procedures performed complications appeared in
only 0.33% of patients who underwent LV-EMB [7].
When LV-EMB is performed, the femoral artery is usu-
ally the access site [3, 8]. The transfemoral site, however, is
associated with the risk of artery puncture and its potential
complications (i.e., false aneurysm, artery-venous fistula) at
the access site and limited due to post-procedural
immobilization. The radial artery is increasingly used for
diagnostic coronary angiography and percutaneous coron-
ary interventions and recently recommended by the to
ESC guidelines for NSTEMI [9]. Lower direct costs, fewer
vascular complications, better patient acceptance and earl-
ier ambulation are some of the direct benefits from using
radial access [10]. When compared to the femoral ap-
proach, less vascular access site complications and reduced
major bleeding have been reported [11–14].
Access-site vascular complications in patients under-
going transradial coronary procedures are rare but may
have relevant clinical consequences [15]. Complications
include spasm, occlusion or perforation of radial artery
(RA), hematoma, pseudoaneurysm, arteriovenous fistula
and nerve injury [16].
The purpose of this study was to analyze the safety
and efficacy of a transradial approach using a sheathless
guiding catheter for left ventricular EMB. In addition,
we aimed to define patients eligible for such an ap-
proach, and to potentially identify patient profiles for




From January 2015 until July 2015 all patients presenting
to our cath lab for EMB work-up of myocardial disease
were evaluated for EMB via transradial access. 18/18 dis-
played a normal Allen test and gave consent for transra-
dial EMB. Further demographic and clinical data on the
patient population is given in Table 1.
Transradial left ventricular EMB
Following local anesthesia, a 6 F sheath (Radifocus Intro-
ducer II, 10 cm, Terumo, Japan) was introduced into the
right radial artery. Upon sheath introduction every pa-
tient received 3000 IU unfractionated heparin and 5 mg
verapamil i.a. A 5 F pigtail catheter (Boston Scientific,
USA) was now advanced into the LV. A long J-wire
(260 cm, 0.03500) was advanced over the pigtail catheter
to hold the ventricular position, the pigtail and the 6 F
radial sheath were removed, and a 7.5 F sheathless mul-
tipurpose guiding catheter (MP1.0, Asahi Intecc, Japan)
was introduced, whereas the dilatator was removed as
soon as the sheathless guiding catheter reached the as-
cending aorta. Following removal of the dilatator the
guiding catheter was carefully advanced over the wire
Table 1 Patient characteristics
Patient characteristics Occluded artery Patent artery T Test
Number of patients (n) 9 9
Normal Allen’s test (%) 100 100
Gender (% female) 44 22 Signifikanz ?
Age (years) 44.9 (29; 63) 47 (25-73) 0.74
Height (cm) 169 (160; 187) 176 (150;193) 0.19
Weight (kg) 77.7 (60;102) 81 (55;113) 0.68
BMI (kg/m2) 27 (21;36) 25 (18;32) 0.56
Creatinine (mg/dl) 0.93 (0.6;1.84) 0.93 (0.67; 1.21) 0.99
Thrombocytes (per nl) 223 (173; 296) 219 (174; 276) 0.83
INR 1.06 (0.92;1.56) 1.05 (0.94; 1.34) 0.90
LVEDP (mmHg) 20 (11;37) 22 (8; 39) 0.692
LVEDD (mm) 52 (38;61) 63 (42; 83) 0.038
LVEF (%) 39 (15; 60) 34 (15; 60) 0.548
Data are presented as mean with data range in brackets
INR International normalized ratio; LVEDP left ventricular end-diastolic pressure;
LVEDD left ventricular end-diastolic diameter; LVEF left ventricular ejection fraction
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connector (Copilot, Abbott Vascular, USA) was con-
nected. The correct position of the guiding catheter tip
was checked in left anterior oblique projection (LAO)
20° projection with the tip of the catheter pointing to
the lateral LV wall. Once the positioning of the catheter
was confirmed 6 ml of contrast agent were injected to
visualize the distance of the tip to the lateral LV wall
(see Fig. 1). Prior to the biopsy, activated clotting timeFig. 1 LV angiography Fluoroscopy in LAO 20° view with injection of
6 ml contrast agent to visualize the position of the 7.5 F MP-1 guiding
catheter inside the left ventricle (tip pointing to the lateral LV wall)(ACT) was checked and adjusted accordingly (ACT
Aim: 250–300 s). Then, a biopsy forceps (B-18110;
1100 mm, 1.8 mm, Medizintechnik Meiners, Germany)
compatible with the 7.5 french sheathless guiding cath-
eter was inserted into the MP1.0 guiding catheter via the
Y connector. The forceps were advanced under fluoros-
copy close to the tip of the guiding catheter. The forceps
were opened inside the guiding catheter and carefully
advanced toward the lateral left ventricular wall. As soon
as resistance was fluoroscopically seen, the jaws were
closed and the forceps immediately retracted into the
guiding catheter. Upon completion of the procedure, the
sheathless guiding catheter was removed and a vascular
closure device (TR Band, Terumo, Japan) was applied
for hemostasis using the “patent hemostasis” protocol
[17]. Briefly, the sheath was pulled out 4–5 cm and the
TR Band was placed around the forearm at the site of
entry. The needle cap and gauze composite was placed
over the site of entry. A pulse oximeter sensor was
placed over the index finger, the TR Band was tightened,
and the sheath was removed. Ipsilateral ulnar artery was
occluded and the hemoband was loosened till ple-
thysmographic signal returned (confirming radial artery
patency) or bleeding occurred. If radial artery patency
could be maintained and hemostasis was achieved, the
bands were left in place for 2 h. The patency of the ra-
dial artery was checked at least once every hour.
Doppler ultrasonography of the radial arteries
Color and pulsed Doppler ultrasound studies were per-
formed by an experienced sonographer within 24 h after
the procedure in all 18 patients. Radial, ulnar and bra-
chial arteries of the access and the opposite forearm
were performed using a Philips iU22 ultrasonography
system (Philips Healthcare, Amsterdam, Netherlands)
featuring a L9-3 MHz linear transducer.
The clinical investigations involved in this study, in-
cluding the obtainment of endomyocardial biopsies,
were part of the routine clinical workup of these pa-
tients. All patients gave written informed consent to the
invasive clinical investigations. The use of the data for
scientific evaluation was approved by the local ethics
committee at the Charité–Universitätsmedizin Berlin,
and all patients gave informed consent for participating
in this framework of the Sonderforschungsbereich
Transregio/SFB-TR 19 “Inflammatory cardiomyopathy”.
Data analysis and statistics
Safety and efficacy parameters were: (1) procedural suc-
cess, (2) quality of biopsy samples as assessed by partici-
pating pathologists, (3) radiation exposure, (4) access
site vessel patency, and (5) relevant access site complica-
tions (defined as: false aneurysm, AV-fistula, drop in
hemoglobin of more than two points without pericardial
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tion for bed rest due to the procedure). (6) Doppler
ultrasonography of the radial and ulnar arteries.
Absolute numbers and percentages were computed to
describe the patient population. Medians (with quartiles)
or means (with standard deviation) were computed as
appropriate. A comparison of qualitative variables be-
tween the groups was performed using the χ2 test. All
statistical analyses were performed using the SAS statis-
tical package, version 9.2 (SAS, Cary, North Carolina).
Results
Patient population
Mean age in both groups was similar (44.9 years in the oc-
cluded radial artery group (RAO) versus 47 years in the
patent radial artery group (RAP)), whereas there were
twice as many female patients in the occluded radial artery
group (RAO 44% versus RAP 22% gibt es hierzu einen
p-Wert? Das muss doch statistisch signifikant sein.).
Both groups had increased mean BMI (BMI in the RAO
group was 27 kg/m2 versus 25 kg/m2 in the RAP group).
Both groups displayed severely impaired LVEF function
(mean LVEF in the RAO group 39% versus 34% in the RAP
group), whereas the left ventricular end-diastolic diameter
was significantly larger in the RAP group (LVEDD in the
RAO group 52 mm versus 63 mm in the RAP group,
P < 0,05)). The blood results were similar in both groups.
Additional patient characteristics can be viewed in Table 1.
Procedural characteristics, safety and efficacy
Depending on the clinical indication, the transradial inva-
sive evaluation encompassed the whole spectrum from
EMB as a standalone procedure or combined left/right
heart catheterization. There was no need to cross over to
femoral access. Thus, the success rate of EMB via transra-
dial access was 100% (18 of 18) in both groups. Table 2
provides a detailed overview of the procedures performed.
The mean duration of the invasive evaluation (RAO
8,24 min versus 6,24 min in the RAP group; P > 0,05)
and the mean dose area product (RAO 1314,12 cGy cm2
versus 1475 cGy cm2 in the RAP group; P > 0,05) were
similar in both groups (Table 2). The number of biopsy
samples harvested were 10 samples per patient in order
to optimize diagnostic accuracy and reduce sampling er-
rors [18]. All biopsy samples harvested via transradialTable 2 Procedural details
Procedural details Occluded arter
Simultaneous coronary angiogram (%) 44.44
ACT (sec) 241
Total fluroscopy time (Min) 8. 24 (5.41; 12.3
Dose area product (cGy cm2) 1314.12 (213; 4
Data are presented as mean with data range in bracketsaccess were graded as good or excellent quality by the
pathologists.
Procedural success/complications
By using the transradial approach, we were able to obtain
left ventricular EMB in all 18 patients. No intraprocedural
complications were encountered in both groups, in par-
ticular no cases of pericardial effusion, thromboembolism
or refractory radial artery spasm. Immediate post-
procedural ambulation could be achieved in all patients as
for no patient any bed rest was assumed necessary.
Postprocedural complications
All patients had radial artery pulse confirmed by ultra-
sonic vascular Doppler 24 h after removal of the guide.
33% (3/9) of the patients developed mild right lower
arm pain in the RAO Group, whereas 1 Patient (11.11%)
developed mild lower arm pain in the RAP group. No
patient developed pain requiring further intervention.
Doppler ultrasonography of the radial and ulnar arteries
All patients (18/18) underwent Color Doppler ultrason-
ography of the radial and ulnar arteries within 24 h after
the procedure was performed (Table 3).
Doppler ultrasonography of the right radial artery re-
vealed radial occlusion in 50% (9/18) of the patients.
The diameter of the radial artery was significantly
smaller in the RAO group (Diameter right radial artery
RAO: 2.52 vs. RAP: 2.86 mm; p = 0.034).
Doppler ultrasonography of the right ulnar artery
showed no significant difference between the two groups
in size (Diameter right ulnar artery (mm) RAO: 2,62 vs.
RAP 2,87 mm; p = 0,182). However, the peak systolic vel-
ocity (PSV) was significantly higher in the RAO group
(PSV (cm/s): RAO 85.2 vs. RAP: 57.2, p = 0.012).
On the contralateral site, the diameter of the left radial
artery was smaller in the RAO group (Diameter left ra-
dial artery (mm) RAO: 2.51 vs. RAP: 2.72 mm; p =
0,061). Peak systolic velocity (PSV) was significantly
lower in the RAO group (PSV (cm/s): RAO 49.15 vs.
RAP: 60.3, p = 0.045).
Left ulnar artery showed no significant difference be-
tween the two groups in size (Diameter left ulnar artery
RAO: 2.53 vs. RAP 2.81 mm; p = 0.14). or PSV (PSV
(cm/s): RAO 55.5 vs. RAP: 50.31, p = 0.248).y Patent artery T Test
44.44
278 0.469
5) 6.47 (3.77;9.57) 0.098
366) 1475 (243;3433) 0.800
Table 3 Doppler ultrasonography of the radial arteries
Doppler ultrasonography Occluded artery Patent artery T Test
Diameter right radial artery (mm) 2.52 (2;2.8)* 2.86 (2.5;3.8) 0.034
Flow Profile (triphasic in %) 0 100
PSV (cm/s) * 38.1 (10;96.3)
Flow Volume (ml/min) * 17.93 (4.5; 59.6)
Diameter right distal ulnar artery (mm) 2.62 (2.1; 3.6) 2.87 (2.3;3.47) 0.182
Flow Profile (triphasic in %) 100 100
PSV (cm/s) 85.2 (60.8;154) 57.2 (36.3; 90) 0.012
Flow Volume (ml/min) 44.72 (18.3;68.3) 47 (10.3; 176) 0.452
Diameter left radial artery (mm) 2.51 (2.2;3) 2. 72 (2.4; 3.3) 0.061
Flow Profile (triphasic in %) 100 100
PSV (cm/s) 49.15 (35; 73.2) 65.4 (35; 88) 0.045
Flow Volume (ml/min) 23.87 (12; 46.6) 34.97 (9.5; 128) 0.196
Diameter left distal ulnar artery (mm) 2.53 (2.2; 3.2) 2.81 (2.3; 3.6) 0.141
Flow Profile (triphasic in %) 100 100
PSV (cm/s) 55.5 (38;70.3) 50. 31 (25.2; 85) 0.248
Flow Volume (ml/min) 30.8 (9.6;55.7) 35. 88 (10.1; 128) 0.364
PSV Peak systolic velocity
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The results of our study showed that EMB using a trans-
radial approach is feasible and efficient.
By using the transradial approach, we were able to
obtain left ventricular EMBs in all 18 patients without the
need to convert to transfemoral access. No intraprocedural
complications were encountered, in particular no cases of
pericardial effusion, thromboembolism or refractory radial
artery spasm. All obtained EMB samples were graded as ex-
cellent quality by the pathologist. These results are similarFig. 2 Color coded Doppler sonography shows origin of the palpable pulse’
artery (Collat from A ulnaris), a pulse was palpable in the distal radial artery evto two recently published series of transradial approach for
LV-EMB [19, 20].
However, our study also showed that a subclinical ra-
dial artery occlusion (RAO) occurs in 50% of patients
after transradial endomyocardial biopsies. On clinical
examination, most of the patients with color-coded Dop-
pler sonography documented RAO (6/9) still had a
‘palpable radial pulse’. This palpable pulse however was
not a radial but an ulnar pulse fed via the palmar arch
(see Fig. 2).in the distal radial artery (A rad dist.): Due to a collateral from the ulnar
en though the proximal radial artery (A radialis prox.) was occluded
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previous studies. This may be due to the fact that in
contrast to previous studies we are among one other
study, the only study with ultrasonic vascular Doppler
based diagnosis of RAO [21]. Although, we were able to
detect a palpable radial pulse in most of the patients
with documented RAO, using ultrasonic vascular Dop-
pler based diagnosis we unmasked a RAO rate of 50%. It
has been shown that patients with RAO can have palp-
able radial pulse even with occluded proximal segment
of the radial artery because of collateral circulation from
the palmar arch [17, 22]. The incidence of RAO can be
detected by vascular Doppler ultrasound only, studies
using RAO ultrasonic vascular Doppler based diagnosis
of RAO, showed that the RAO rate was well correlated
with the size of transradial sheath (13.7 vs 30.5% in 5 Fr
vs 6 Fr sheath) [23].
Secondly, although a French study on adult patients
with suspected coronary artery disease reported a radial
artery diameter to be 3.7 ± 0.8 mm [24] we observed much
smaller radial artery diameter of 2.7 ± 0.4 mm (range: 2.0-
3.8 mm). These observed radial diameters are more simi-
lar to diameters observed in Asian populations [25].
Thirdly patient in both groups were young and the
percentage of female patients was high in both groups,
whereas there were twice as many female patients in the
RAO Group.
Recently, a univariate analysis of predictors of RAO in-
cluding patients who underwent diagnostic angiography
and angioplasty with a 5 French and 6 French sheath
showed that the presence of younger age and female sex
were again strong predictors of post-procedural RAO. The
mean age of that study was significantly higher than our
mean age (Mean age: 5 F (65.1 ± 10.8) and 6 (64.9 ± 11.0)),
and the percentage of females was similar than in our study
(female patients 5 F 97 (36.6%) and 6 F 186 (38.4%) [17].
Another predictor of RAO in a prospective study of RAO
was diabetes mellitus [23].
In our study, a total of 3 patients had a radial artery
diameter less than the radial sheath diameter used for TR-
EMB (7.5 Fr with an outer diameter of 2.49 mm). All of
these 3 patients developed RAO. Therefore, in our study,
the occlusion rate was 100% in patients with radial artery
to sheath ratio ≤1 as compared to 40% if the ratio was >1.
The artery to sheath ratio seems to be a contributing
factor for RAO since Saito et al. showed that a radial ar-
tery diameter/sheath-diameter ratio <1 is associated with
a reduction in distal flow [26]. Interestingly, even in the
RAP group the post procedural PSV was lower in the ra-
dial artery (PSV 38,1 cm/s (10; 96,3)). However, Garg
et al. showed that radial artery to sheath ratio ≤1 was
not an independent predictor for RAO on multivariate
analysis in patients undergoing coronary interventions
using a 6 French guiding catheter [25].Conclusion
In conclusion, the present report confirms the feasibility of
the transradial approach using a sheathless catheter for
LV-EMB. However, duplex sonography revealed a con-
siderable frequency of post procedural asymptomatic
radial occlusions. Gender, age, Diabetes mellitus, radial
artery inner diameter ≤2.5 mm and lower radial peak
systolic velocity of ≤ 50 cm/s are likely predictors of RAO.
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